{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:38:05Z","timestamp":1788482285497,"version":"build-2803163510"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"50","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rational:<\/jats:title>\n            <jats:p>The growing population of young cancer survivors and a trend toward postponing pregnancy until later years in life are leading to a deeper attention towards understanding treatment-induced sequelae, and, in particular, the effects of cancer and\/or treatment on fertility. Nowadays, the infertility risks potentially associated with molecular targeted therapies are not established, and clinical reports are sparse. Moreover, the increasing use of molecular targeted drugs in the adjuvant setting and in diseases with better prognosis makes preservation of fertility a major topic in current research.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient's concerns:<\/jats:title>\n            <jats:p>Here, we report the case of an 18-year-old woman, with a 3-cm superficial lump of the right breast, who had no remarkable family or medical history. Menarche had occurred at the age of 14 years, with normal regular periods.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>High-grade angiosarcoma, with metastatic progression and multiple relapse, was diagnosed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>After diagnosis, right radical mastectomy was carried out with no evidence of residual disease. No adjuvant treatment was delivered. Lymph node metastasis were found later and chemotherapy with doxorubicin 25\u200amg\/m<jats:sup>2<\/jats:sup>\/day and ifosfamide 1\u200ag\/m<jats:sup>2<\/jats:sup>\/day (both on days 1\u20133) every 21 days was administered. During treatment, the patient reported menstrual irregularities but no amenorrhea. Due to further local relapse a few years later, the patient was treated for progressive metastatic disease with gemcitabine 1000\u200amg\/m<jats:sup>2<\/jats:sup> on days 1 and 8 every 21 days for 6 cycles, and underwent surgery, followed by pegylated liposomal doxorubicin, 50 mg\/m<jats:sup>2<\/jats:sup> on day 1 every 28 days. After further disease progression 5 years after first diagnosis, pazopanib was administered at a dose of 800\u200amg daily for 10 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient experienced a transient ovarian insufficiency possibly due to pazopanib. Since amenorrhea developed within 2 months from the initiation of pazopanib treatment and menses returned regularly only after discontinuation of the treatment itself.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>This is the first case report that strongly suggests a correlation between pazopanib exposure and development of ovarian insufficiency. Our case tantalizes to inspire additional preclinical and clinical research on the true incidence, possible dose dependence, and reversibility of pazopanib (and other TKIs) -induced ovarian failure.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000018089","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T13:50:54Z","timestamp":1576590654000},"page":"e18089","source":"Crossref","is-referenced-by-count":15,"title":["Primary ovarian insufficiency associated with pazopanib therapy in a breast angiosarcoma patient"],"prefix":"10.1097","volume":"98","author":[{"given":"Rita","family":"De Sanctis","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center \u2013 IRCCS, Rozzano (MI)"},{"name":"Humanitas University, Department of Biomedical Sciences, Pieve Emanuele \u2013 Milan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Lorenzi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center \u2013 IRCCS, Rozzano (MI)"},{"name":"Humanitas University, Department of Biomedical Sciences, Pieve Emanuele \u2013 Milan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Agostinetto","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center \u2013 IRCCS, Rozzano (MI)"},{"name":"Humanitas University, Department of Biomedical Sciences, Pieve Emanuele \u2013 Milan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"D\u2019Amico","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, Endocrinology-Pituitary Disease, \u201cSapienza\u201d University of Rome, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Simonelli","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center \u2013 IRCCS, Rozzano (MI)"},{"name":"Humanitas University, Department of Biomedical Sciences, Pieve Emanuele \u2013 Milan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Humanitas Cancer Center, Humanitas Clinical and Research Center \u2013 IRCCS, Rozzano (MI)"},{"name":"Humanitas University, Department of Biomedical Sciences, Pieve Emanuele \u2013 Milan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,12]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"163","DOI":"10.7150\/ijms.3827","article-title":"Cancer survivors in the United States: a review of the literature and a call to action","volume":"9","author":"Valdivieso","year":"2012","journal-title":"Int J Med Sci"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3322\/caac.21149","article-title":"Cancer treatment and survivorship statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1097\/00000478-198110000-00005","article-title":"Angiosarcoma and other vascular tumors of the breast","volume":"5","author":"Donnell","year":"1981","journal-title":"Am J Surg Pathol"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1093\/annonc\/mdm381","article-title":"Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases","volume":"18","author":"Fayette","year":"2007","journal-title":"Ann Oncol"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/1097-0142(19821115)50:10<2000::AID-CNCR2820501004>3.0.CO;2-U","article-title":"Multimodality therapy in the management of angiosarcoma of the breast","volume":"50","author":"Antman","year":"1982","journal-title":"Cancer"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/0360-3016(93)90395-C","article-title":"Primary soft tissue sarcomas of the breast: local-regional control with post-operative radiotherapy","volume":"27","author":"Johnstone","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/jso.20110","article-title":"Primary sarcoma of the breast","volume":"87","author":"Pandey","year":"2004","journal-title":"J Surg Oncol"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/annonc\/mdu460","article-title":"Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials","volume":"25","author":"Le Cesne","year":"2014","journal-title":"Ann Oncol"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00432-015-2065-4","article-title":"Adjuvant chemotherapy for soft tissue sarcomas: a 10-year mono-institutional experience","volume":"142","author":"Brunello","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1200\/JCO.2008.17.3146","article-title":"Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study","volume":"26","author":"Penel","year":"2008","journal-title":"J Clin Oncol"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/annonc\/mdr066","article-title":"Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network","volume":"23","author":"Stacchiotti","year":"2012","journal-title":"Ann Oncol"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/annonc\/mds607","article-title":"Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy","volume":"24","author":"Santoro","year":"2013","journal-title":"Ann Oncol"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1517\/13543784.17.2.253","article-title":"Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma","volume":"17","author":"Sonpavde","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"Van der Graaf","year":"2012","journal-title":"Lancet"},{"issue":"(Suppl 6)","key":"R17-20230915","doi-asserted-by":"crossref","first-page":"vi160","DOI":"10.1093\/annonc\/mdt199","article-title":"Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Peccatori","year":"2013","journal-title":"Ann Oncol"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1530\/rep.1.00978","article-title":"Platelet-derived growth factor modulates the primordial to primary follicle transition","volume":"131","author":"Nilsson","year":"2006","journal-title":"Reproduction"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1210\/en.2004-0765","article-title":"The vascular endothelial growth factor (VEGF)\/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent","volume":"146","author":"Pauli","year":"2005","journal-title":"Endocrinology"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1177\/1933719115584448","article-title":"Effects of pazopanib, sunitinib, and sorafenib, anti-VEGF agents, on the growth of experimental endometriosis in rats","volume":"22","author":"Yildiz","year":"2015","journal-title":"Reprod Sci Thousand Oaks Calif"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2016.08.005","article-title":"Infertility risk and teratogenicity of molecularly targeted anticancer therapy: a challenging issue","volume":"107","author":"Lorenzi","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3892\/mco.2017.1237","article-title":"Ovarian function following targeted anti-angiogenic therapy with bevacizumab","volume":"6","author":"Imai","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1200\/JCO.2018.78.1914","article-title":"Fertility preservation in patients with cancer: ASCO clinical practice guideline update","volume":"36","author":"Oktay","year":"2018","journal-title":"J Clin Oncol"},{"key":"R26-20230915","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2015.62.9170","article-title":"Adjuvant imatinib for high-risk gi stromal tumor: analysis of a randomized trial","volume":"34","author":"Joensuu","year":"2016","journal-title":"J Clin Oncol"},{"key":"R27-20230915","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1056\/NEJMoa1611406","article-title":"Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy","volume":"375","author":"Ravaud","year":"2016","journal-title":"N Engl J Med"},{"key":"R28-20230915","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000018089","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T23:44:02Z","timestamp":1694821442000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000018089"}},"subtitle":["A CARE-compliant case report"],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":27,"journal-issue":{"issue":"50","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000018089","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}